GLP-1 medications are widely used for diabetes and weight management, but some side effectssuch as dry mouth and oral discomfortare discussed less often
Some patients have already reached their goal weight and are looking to maintain their results while continuing to support metabolic health
Symptoms, examination, medication history, eye care, and imaging may also be necessary
We believe HRS9531 has the potential to make a meaningful difference in the lives of people living with obesity. The HRS9531 6 mg results further validate the potential of KAI-9531 to be a transformative therapy for patients living with obesity and overweight, and were excited to start our global Phase 3 program by year-end to evaluate both higher doses and longer treatment durations to unlock the full potential of KAI-9531, said Ron Renaud, President and Chief Executive Officer, Kailera
When the dose was increased from 1 mg to 2.4 mg per week, PwO without T2D lost on average 15% of their starting weight [18, 19]
This represents unknown risk, not confirmed hazard